


Radiopharmaceuticals : Has There been progress?

Neal D. Shore, MD
IPCU 2016


Place in therapy: Radium 223



*Such as abiraterone acetate or enzalutamide

†Not drawn to scale

Proposed Location of Radium 223: Trough Transition




ALSYMPCA: Study Design

PATIENTS (N=921)

- Confirmed symptomatic CRPC
- ≥ 2 bone metastases
- No known visceral metastases
- Post-docetaxel, unfit for docetaxel, or refused docetaxel^a

STRATIFICATION

- Total ALP: < 220 U/L vs ≥ 220 U/L
- Bisphosphonate use: Yes vs No
- Prior docetaxel: Yes vs No



Radium-223 (50 kBq/kg IV) 6 injections at 4-week intervals + best standard of care^b

Placebo (saline) 6 injections at 4-week intervals + best standard of care^b

- 136 centers in 19 countries
- Planned follow-up is 3 years

ALSYMPCA was halted early after the positive efficacy results reported from a planned interim analysis of 809 patients with 314 deaths occurred. An updated analysis of efficacy and safety was performed from all 921 enrolled patients when 528 deaths had occurred.

ALP, alkaline phosphatase; ALSYMPCA, Alpharadin in Symptomatic Prostate Cancer; CRPC, castration-resistant prostate cancer.

a. Unfit for docetaxel includes patients who were ineligible for docetaxel, refused docetaxel, or lived where docetaxel was unavailable.

b. Best standard of care defined as a routine standard of care at each center, e.g., local external beam radiation therapy, corticosteroids, antiandrogens, estrogens (e.g., stilbestrol), estramustine, or ketoconazole.

SOURCE: Parker C, et al. *N Engl J Med.* 2013;369(3):213–223.

ALSYMPCA summary

- In the ALSYMPCA trial, Xofigo[®] compared with placebo in patients with CRPC and symptomatic bone metastases^{1,2}
 - Established efficacy with an overall survival (OS) benefit of 3.6 months ($P<0.001$)
 - Significantly prolonged the time to first SSE* (15.6 vs 9.8 months, $P<0.001$)
 - Had a favorable safety profile with low rates of myelosuppression

* Secondary endpoint


ALSYMPCA: ALpharadin in SYMptomatic Prostate CAncer; CRPC: castration resistant prostate cancer, OS: overall survival, SSE: symptomatic skeletal event.

1. Parker et al. N Engl J Med. 2013;369:213-223.

2. Xofigo[®] (radium Ra 223 dichloride) injection [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc.; May 2013.

ALSYMPCA Updated Analysis: Radium-223 Significantly Improved Overall Survival

The updated analysis confirmed the 30% reduction in risk of death (HR=0.70) for patients in the radium-223 group compared with placebo.



— Radium-223	614	578	504	369	274	178	105	60	41	18	7	1	0	0
— Placebo	307	288	228	157	103	67	39	24	14	7	4	2	1	0

CI, confidence interval; HR, hazard ratio; OS, overall survival.

SOURCE: Parker C, et al. *N Engl J Med.* 2013;369(3):213–223.

Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective

Neal D. Shore

Radium-223 dichloride (radium-223) is an important therapeutic option for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases, and no visceral disease. The unique mechanism of action of this first-in-class alpha-emitting radiopharmaceutical underlies its favorable safety profile and low incidence of myelosuppression. In the pivotal phase 3 ALpharadin in SYMptomatic Prostate CAncer Patients study, radium-223 reduced the risk of death by 30% and prolonged time to first symptomatic skeletal event by 5.8 months. This article summarizes current guidelines and clinical studies that led to the approval of radium-223 as an overall survival therapy, and discusses the urologist's perspective on using radium-223 in clinical practice. UROLOGY ■: ■-■, 2015. © 2015 Elsevier Inc.

Prostate cancer is the fourth leading cause of US cancer deaths and the most common cancer managed by urologists, with >233,000 new cases estimated for 2014.¹ On diagnosis, approximately 12% of patients will have locally advanced disease, and 4% of newly diagnosed patients will present with metastatic disease.¹ Although newly diagnosed localized disease may be cured with interventional therapies, approximately 30% of patients develop recurrent disease and may progress to castration-resistant prostate cancer (CRPC).^{1,2} As the clinicians chiefly responsible for diagnosing, treating, and monitoring prostate cancer patients, urologists are uniquely positioned to provide a detailed discussion of therapeutic options and promote shared decision making with patients regarding approved CRPC treatment options.


Although CRPC treatment options with unique mechanisms of action (MOAs) have burgeoned since 2010, the disease eventually evolves via selective pres-

or surgical intervention.^{4,5} Bone-metastatic CRPC (mCRPC)—associated events can cause functional disability, reduced quality of life (QOL), further complications that may impact survival, and ultimately health care cost escalations.^{4,6} Urologists dedicated to evaluating and managing therapeutic options for patients with progressive CRPC must be knowledgeable of approved therapies that can delay disease progression and prolong survival, and they must proactively manage the relatively ubiquitous metastatic skeletal disease and the associated potential complications.


Radium-223 dichloride (radium-223) is a first-in-class alpha-emitting radiopharmaceutical approved for treating CRPC patients with symptomatic bone metastases with no known visceral metastatic disease.⁷ Clinicians caring for patients with progressive CRPC should understand the radium-223 MOA, its role in the treatment plan for appropriate CRPC patients, and its administration, efficacy, and safety profile. This review summarizes

ALSYMPCA: OS by Prior Docetaxel Use

Prior docetaxel use



NO prior docetaxel use





**US EXPANDED ACCESS PROGRAM (EAP)
SAFETY AND EXPLORATORY EFFICACY ANALYSIS**

Rationale and objectives for EAP studies

- Building off of the findings of the ALSYMPCA trial, the EAP for Xofigo[®] was designed to:¹⁻³
 - Provide earlier access of Xofigo[®] to CRPC patients with bone metastases prior to regulatory approval
 - Monitor long-term safety and efficacy data of Xofigo[®]

Shore N, et al. Radium-223 Dichloride in Expanded-Access Setting in the US: Overall and Concurrent Experience with Abiraterone or Enzalutamide (AUA 2015, Abstract 15-6266)

Abstract 15-6266

Radium-223 Dichloride in Expanded-Access Setting in the United States: Overall and Concurrent Experience With Abiraterone or Enzalutamide

Near Shore,¹ Nicholas J. Vogelzang,² Daniel C. Fernandez,³ Michael J. Morris,⁴ Andrei Iagaru,⁵ Alan Brown, Jr,⁶ Christopher Sweeney,⁷ Matthew R. Smith,⁸ Adam P. Dicker,⁹ Yu-Ning Wong,¹⁰ Keith Bangerter,¹¹ Jeremy Gratt,¹¹ Oana Petrenciu,¹¹ Oliver Sartor¹²

¹Carolina Urologic Research Center, Myrtle Beach, SC, USA; ²Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; ³H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Stanford University, Stanford, CA, USA; ⁶21st Century Oncology, Fort Myers, FL, USA; ⁷Dana-Farber Cancer Institute, Boston, MA, USA; ⁸Massachusetts General Hospital, Boston, MA, USA; ⁹Thomas Jefferson University, Philadelphia, PA, USA; ¹⁰Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA; ¹¹Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; ¹²Tulane Cancer Center, New Orleans, LA, USA

BACKGROUND

Radium-223 Dichloride (Radium-223)

- First approved alpha-emitting radiopharmaceutical with a potent and highly targeted cytotoxic effect on bone metastases¹
- In phase 3 ALSYMPCA, radium-223 + best standard of care (BSOC) compared with placebo + BSOC in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases²
 - Established efficacy with overall survival (OS) benefit; improved OS by 2.6 months (HR = 0.70, 95% CI, 0.58-0.85; P < 0.001)
 - Had a favorable safety profile with low rates of myelosuppression

US Expanded Access Program (EAP) (15995)

- A phase 2, prospective, interventional, open-label, multicenter study conducted in the United States and designed to
 - Provide early access of radium-223 to patients with CRPC and symptomatic bone metastases prior to regulatory approval
 - Monitor acute and long-term safety of radium-223


RATIONALE AND OBJECTIVE

- At the time of this study, the new hormonal agents abiraterone and enzalutamide were available and administered prior to start of, during, and following the US EAP treatment period
- The objective of this study is to present safety and OS in US patients from EAP who received prior and concurrent abiraterone or enzalutamide
 - Data presented here are updated since the abstract submission

METHODS

- US EAP study design and end points are shown in **Figure 1**
 - Eligibility criteria were similar to those of ALSYMPCA²

Figure 1. US EAP Study Design



End Points

Primary safety (assessed during treatment and up to 30 days post-treatment acute) and up to 30 days post-treatment through follow-up (6 mo until death or study termination) and quality of life. Exploratory efficacy: overall survival, time to first SSE, time to disease progression, changes in ALP and PSA, confirmed ALP and PSA response, SALLP normalization, and time to SALLP and PSA progression.

Major use of opioid or morphine analgesics for cancer-related bone pain or external beam radiation therapy within 12 months before or throughout study period; or increased pain requiring rescue analgesics; or non-radiation-related events including grade 2+ anemia, neutropenia, thrombocytopenia, or any adverse event leading to discontinuation; grade 2+ liver or renal toxicity; grade 3+ hypokalemia; or grade 2+ hypocalcemia. Exploratory toxicity: grade 2+ treatment-emergent adverse events (TEAE) leading to discontinuation; grade 3+ SALLP; or grade 2+ hypocalcemia requiring treatment. PSA: prostate-specific antigen; SALLP: serious adverse events; SSE: symptomatic skeletal events; ALP: total alkaline phosphatase; TEAE: treatment-emergent adverse events.

- Treatment period is defined as the time from first dose of study treatment through last dose + 30 days
- Follow-up was short (~3-9 mo) because of study termination by the sponsor due to commercial availability of radium-223
- Prior therapies were defined as those taken prior to and stopped at study entry
 - Concurrent therapies were defined as those started and received with radium-223 or received prior to and with radium-223 up to 30 days after last radium-223 dose
- All variables were analyzed primarily by descriptive statistics

RESULTS

Prior and Concurrent Systemic Anticancer Therapy

- Prior anticancer therapy was common to what one would see in this patient population (**Table 1**)

Table 1. Select Prior and Concurrent Systemic Anticancer Therapy

Anticancer Therapy, n (%)	EAP N = 184*	
	Prior	Concurrent
Bicalutamide	147 (80)	9 (5)
Abiraterone	130 (65)	29 (14)
Docetaxel†	110 (60)	4 (2)
Enzalutamide	59 (32)	15 (8)
Ketanserin‡	48 (26)	3 (2)
Nilotamib§	39 (21)	3 (2)
Cabazitaxel¶	33 (18)	4 (2)
Flutamide	18 (10)	2 (1)
Denosumab	10 (5)	31 (17)
Zoledronic acid	0 (0)	17 (9)

*A patient could have 1 medication; therefore, the sum of medication counts and percentages may not equal the total count. Agents were not given with radium-223, but were started within a 30-day period following the last radium-223 injection.

Prior Abiraterone or Enzalutamide

- 120/184 (65%) patients received prior abiraterone and 59/184 (32%) patients received prior enzalutamide
- Baseline characteristics of patients who received prior abiraterone or enzalutamide were generally similar to those of patients who had not received these agents (**Table 2**)
- 72% and 81% of patients with prior abiraterone or enzalutamide, respectively, had prior use of docetaxel (**Table 2**)
- Patients who had prior abiraterone or enzalutamide had higher baseline alkaline phosphatase and prostate-specific antigen (PSA) than patients with no prior abiraterone or enzalutamide (**Table 2**)

Table 2. Demographics and Baseline Characteristics of Patients Who Received Prior Abiraterone or Enzalutamide

	Abiraterone		Enzalutamide	
	Yes n = 120	No n = 64	Yes n = 59	No n = 125
Age, median (range), y	71 (47-97)	69 (47-89)	69 (47-85)	71 (47-97)
Weight, median (range), kg	84 (49-134)	85 (49-130)	84 (62-133)	86 (49-138)
ECOG PS 0-1, n (%)	107 (89)	58 (91)	53 (90)	112 (90)
ALP, median (range), U/L	107 (34-1160)	125 (38-795)	209 (59-1160)	135 (34-857)
PSA, median (range), ng/mL	187 (13-550)	108 (1-1660)	222 (2-5150)	117 (1-13900)
Albumin, median (range), g/dL	4 (3-5)	4 (3-5)	4 (3-5)	4 (3-5)
Hemoglobin, median (range), g/dL	12 (8-15)	12 (10-15)	12 (9-15)	12 (8-15)
Current use of bisphosphonates, n (%)*	11 (9)	4 (6)	3 (5)	14 (11)
Current use of denosumab, n (%)†	17 (14)	14 (22)	12 (20)	19 (15)
Prior use of docetaxel, n (%)‡	86 (72)	24 (38)	48 (81)	62 (50)

*Current use defined as use during the treatment period.

†ALP = alkaline phosphatase; ECOG PS = Eastern Cooperative Oncology Group performance status; PSA = prostate-specific antigen.

- Safety profiles of radium-223 were similar regardless of prior exposure to abiraterone or enzalutamide (**Table 3**)
 - Most common grade 3-4 events were anemia and thrombocytopenia

Table 3. Summary of AE Categories of Patients Who Received Prior Abiraterone or Enzalutamide During Treatment Period

AE Category, n (%)	Abiraterone		Enzalutamide	
	Yes n = 120	No n = 64	Yes n = 59	No n = 125
Grade 3-4 TEAE	45 (38)	22 (34)	23 (39)	44 (35)
Treatment-related TEAE	44 (37)	22 (34)	31 (53)	62 (50)
Serious AE	31 (26)	14 (22)	18 (31)	27 (22)
Discontinuation due to TEAE	21 (18)	9 (14)	12 (20)	18 (14)

AE = adverse event; TEAE = treatment-emergent adverse event.

Concurrent Abiraterone or Enzalutamide

- The number of patients who received concurrent abiraterone or enzalutamide was small; results should be interpreted with caution
- 25/184 (14%) patients received concurrent abiraterone, and 15/184 (8%) patients received concurrent enzalutamide (**Table 4**)
 - Among patients with concurrent abiraterone, 8/25 (32%) had received prior enzalutamide
 - Among patients with concurrent enzalutamide, 14/15 (93%) had received prior abiraterone

Table 4. Summary of Patients Who Received Medication Sequences Including Abiraterone, Enzalutamide, and Docetaxel

Concurrent abiraterone and prior enzalutamide or no prior abiraterone	Patients, n (%)	
	Yes	No
Concurrent abiraterone and prior enzalutamide	8 (25)	17 (25)
No prior abiraterone	15 (15)	110 (15)
Concurrent enzalutamide and prior abiraterone	14 (15)	93 (93)
No prior abiraterone	1 (1)	114 (104)
Concurrent enzalutamide and prior docetaxel	11 (15)	113 (15)

The patients received both abiraterone and enzalutamide concurrently with radium-223 and had no prior abiraterone or enzalutamide. The characteristics in both groups.

- Baseline characteristics of patients who received concurrent abiraterone or enzalutamide were generally similar to those in the overall population (**Table 5**), with some exceptions
 - PSA and prior use of docetaxel were higher in patients with concurrent enzalutamide than in patients with concurrent abiraterone or the overall population

Table 5. Demographics and Baseline Characteristics of Patients Who Received Concurrent Abiraterone or Enzalutamide

	Abiraterone		Enzalutamide		EAP Overall	
	n = 25	n = 15	n = 15	n = 110	n = 184	n = 184
Age, median (range), y	66 (47-81)	70 (54-84)	70 (47-97)	71 (47-97)	70 (47-97)	70 (47-97)
Weight, median (range), kg	86 (58-109)	89 (65-110)	86 (49-138)	86 (49-138)	86 (49-138)	86 (49-138)
ECOG PS 0-1, n (%)	25 (100)	14 (93)	165 (90)	165 (90)	165 (90)	165 (90)
ALP, median (range), U/L	188 (51-573)	188 (86-513)	154 (34-1160)	154 (34-1160)	154 (34-1160)	154 (34-1160)
PSA, median (range), ng/mL	241 (12-88)	322 (1-2320)	129 (1-15150)	129 (1-15150)	129 (1-15150)	129 (1-15150)
Albumin, median (range), g/dL	4 (3-5)	4 (3-4)	4 (3-5)	4 (3-5)	4 (3-5)	4 (3-5)
Hemoglobin, median (range), g/dL	12 (10-15)	11 (9-15)	12 (8-15)	12 (8-15)	12 (8-15)	12 (8-15)
Current use of bisphosphonates, n (%)*	5 (20)	3 (20)	17 (10)	17 (10)	17 (10)	17 (10)
Current use of denosumab, n (%)†	5 (20)	4 (27)	31 (17)	31 (17)	31 (17)	31 (17)
Prior use of docetaxel, n (%)‡	11 (44)	11 (73)	130 (66)	130 (66)	130 (66)	130 (66)

*Current use defined as use during the treatment period.

†ALP = alkaline phosphatase; ECOG PS = Eastern Cooperative Oncology Group performance status; PSA = prostate-specific antigen.

- Safety profiles of radium-223 were generally similar regardless of whether patients received concurrent abiraterone or enzalutamide (**Table 6**)
 - Most frequently occurring grade 3-4 treatment-emergent adverse events were anemia (abiraterone 16%, enzalutamide 13%), thrombocytopenia (abiraterone 4%, enzalutamide 0%), and back pain (abiraterone 0%, enzalutamide 13%)

Table 6. Summary of AE Categories of Patients Who Received Concurrent Abiraterone or Enzalutamide During Treatment Period


AE Category, n (%)	Abiraterone		Enzalutamide		EAP Overall	
	n = 25	n = 15	n = 15	n = 110	n = 184	n = 184
Grade 3-4 TEAE	10 (40)	6 (40)	67 (36)	67 (36)	67 (36)	67 (36)
Treatment-related TEAE	10 (40)	12 (80)	53 (28)	53 (28)	53 (28)	53 (28)
Serious AE	6 (24)	4 (27)	49 (24)	49 (24)	49 (24)	49 (24)
Discontinuation due to TEAE	6 (24)	4 (27)	30 (16)	30 (16)	30 (16)	30 (16)

AE = adverse event; EAP = Expanded Access Program; TEAE = treatment-emergent adverse event.

Overall Survival: Prior Abiraterone or Enzalutamide

- Median OS of patients with prior abiraterone (15.6 mo, n = 120) and prior enzalutamide and/or enzalutamide (15.6 mo, n = 131) was similar to that of the overall EAP population (17 mo, n = 184) (**Figure 2A, C, and D**)

Figure 2. Overall Survival of Patients Who Received Prior Abiraterone (A), Enzalutamide (B), Abiraterone and/or Enzalutamide (C), and Overall EAP Population (D)




EAP = Expanded Access Program; NE = not evaluable due to a short follow-up time and large percentage of patients (70%) still alive at the time of analysis.

Overall Survival: Concurrent Abiraterone or Enzalutamide

- Median OS for patients with (n = 25) and without (n = 159) concurrent abiraterone were not estimable and 15.6 months, respectively
- Median OS for patients with (n = 15) and without (n = 169) concurrent enzalutamide were 10.7 and 17.1 months, respectively
- Patients who received concurrent abiraterone and/or enzalutamide with no prior abiraterone or enzalutamide (n = 17) appeared to have longer OS than those who did not (**Figure 3A**)
- The effect of concurrent abiraterone and/or enzalutamide was not as pronounced in patients who had received prior abiraterone or enzalutamide (**Figure 3B**)

Figure 3. Overall Survival of Patients Who Received Concurrent Abiraterone and/or Enzalutamide (With No Prior Abiraterone or Enzalutamide [A] and With Prior Abiraterone or Enzalutamide [B])



*Concurrent abiraterone and/or enzalutamide with no prior abiraterone or enzalutamide. †Concurrent abiraterone and/or enzalutamide with prior abiraterone or enzalutamide. ‡NE = not evaluable due to a short follow-up time and large percentage of patients (70%) still alive at the time of analysis.

CONCLUSIONS

- In this is EAP, radium-223 was safe and well tolerated regardless of prior or concurrent exposure to abiraterone and/or enzalutamide
- OS was comparable in radium-223-treated patients who received prior abiraterone and/or enzalutamide versus the overall EAP population
- Initial findings of OS in the small numbers of patients receiving concurrent abiraterone or enzalutamide are indeterminate. Current trials are under way to assess radium-223 combinations

REFERENCES

- Xoligo (radium Ra-223 dichloride) injection, for intravenous use [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2013.
- Parker C, et al. *N Engl J Med.* 2013;369:213-223.

Acknowledgments
The study was supported by Bayer HealthCare Pharmaceuticals, Inc.
The authors wish to thank CelStratigraphy Communications for editorial and creative assistance in the preparation of this poster.



Copyright © 2015, American Society of Clinical Oncology. All rights reserved. Reproduction in whole or in part without permission from the author is prohibited.

Radium-223 Dichloride in Expanded-Access Setting in the United States: Overall and Concurrent Experience With Abiraterone or Enzalutamide

Neal Shore,¹ Nicholas J. Vogelzang,² Daniel C. Fernandez,³ Michael J. Morris,⁴ Andrei Iagaru,⁵ Alan Brown, Jr,⁶ Christopher Sweeney,⁷ Matthew R. Smith,⁸ Adam P. Dicker,⁹ Yu-Ning Wong,¹⁰ Keith Bangerter,¹¹ Jeremy Gratt,¹¹ Oana Petrenciu,¹¹ Oliver Sartor¹²

¹Carolina Urologic Research Center, Myrtle Beach, SC, USA; ²Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; ³H. Lee Moffitt Cancer Center, Tampa, FL, USA; ⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA; ⁵Stanford University, Stanford, CA, USA; ⁶21st Century Oncology, Fort Myers, FL, USA; ⁷Dana-Farber Cancer Institute, Boston, MA, USA; ⁸Massachusetts General Hospital, Boston, MA, USA; ⁹Thomas Jefferson University, Philadelphia, PA, USA; ¹⁰Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA; ¹¹Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ, USA; ¹²Tulane Cancer Center, New Orleans, LA, USA

Radium-223 Dichloride

- First approved alpha-emitter highly targeted cytotoxic
- In phase 3 ALSYMPCA, compared with placebo prostate cancer (CRPC)
 - Established efficacy vs 2.6 months (HR = 0.74)
 - Had a favorable safety profile

US Expanded Access Program

- A phase 2, prospective, open-label study conducted in the United States
- Provide early access to symptomatic bone metastases
- Monitor acute and long-term toxicity


RATIONALE

- At the time of this study, abiraterone and enzalutamide were available and following the US EAP
- The objective of this study was to assess the overall EAP experience in patients who received prior abiraterone or enzalutamide
- Data presented here

US EAP Study Design

- Eligibility criteria were as follows:

Figure 1. US EAP Study Design



End Points

- Primary: safety (assessed during post-treatment through follow-up)
- Exploratory efficacy: overall survival and PSA, confirmed SAP and PSR

*Median time to onset of nonfatal adverse events (AEs) during treatment. **Median overall survival (OS) by Short Form-12 (SF-12) - based Pain Inventory Short Form-12 (SF-12Pain) - based Composite Disability Index (CDI). ***Median time to onset of pain-specific AE (PSA) in the population (PSA) = treatment-emergent.


CONCLUSIONS

- In this is EAP, radium-223 was safe and well tolerated regardless of prior or concurrent exposure to abiraterone and/or enzalutamide
- OS was comparable in radium-223-treated patients who received prior abiraterone and/or enzalutamide versus the overall EAP population
- Initial findings of OS in the small numbers of patients receiving concurrent abiraterone or enzalutamide are indeterminate. Current trials are under way to assess radium-223 combinations

Overall Survival: Concurrent Abiraterone or Enzalutamide

- Median OS for patients with (n = 25) and without (n = 159) concurrent abiraterone or enzalutamide were not estimable and 15.6 months, respectively
- Median OS for patients with (n = 15) and without (n = 169) concurrent enzalutamide were 10.7 and 17.1 months, respectively
- Patients who received concurrent abiraterone and/or enzalutamide with no prior abiraterone or enzalutamide (n = 17) appeared to have longer OS than those who did not (Figure 3A)
- The effect of concurrent abiraterone and/or enzalutamide was not as pronounced in patients who had received prior abiraterone or enzalutamide (Figure 3B)

Figure 3. Overall Survival of Patients Who Received Concurrent Abiraterone and/or Enzalutamide (With No Prior Abiraterone or Enzalutamide [A] and With Prior Abiraterone or Enzalutamide [B])



CONCLUSIONS

- In this is EAP, radium-223 was safe and well tolerated regardless of prior or concurrent exposure to abiraterone and/or enzalutamide
- OS was comparable in radium-223-treated patients who received prior abiraterone and/or enzalutamide versus the overall EAP population
- Initial findings of OS in the small numbers of patients receiving concurrent abiraterone or enzalutamide are indeterminate. Current trials are under way to assess radium-223 combinations

REFERENCES

1. Xofigo (radium Ra 223 dichloride) injection, for intravenous use [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2013.
2. Parker et al. *N Engl J Med.* 2013;369:213-220.

Acknowledgments

The study was supported by Bayer HealthCare Pharmaceuticals, Inc. The authors wish to thank SolStrategy Communications for editorial and creative assistance in the preparation of this poster.



Copy of this poster is available for personal use only and may not be reproduced without permission from the author.

Sartor O, et al. Radium-223 Dichloride Experience in Pretreated Patients: Early Access Program Setting (ASCO 2015, Abstract 5063)

Abstract 5063

Radium-223 Dichloride Experience in Pretreated Patients: Early Access Program Setting

Oliver Sartor,¹ Daniel C. Fernandez,² Michael J. Morris,³ Andrei Iagaru,⁴ Alan Brown Jr,⁵ Fabio Almeida,⁶ Christopher Sweeney,⁷ Matthew R. Smith,⁸ Adam P. Dicker,⁹ Yu-Ning Wong,¹⁰ Neal Shore,¹¹ Jeremy Gratt,¹² Oana Petrenciuc,¹² Joseph Germino,¹² Nicholas J. Vogelzang¹³

¹Tulane Cancer Center, New Orleans, LA; ²H. Lee Moffitt Cancer Center, Tampa, FL; ³Memorial Sloan Kettering Cancer Center, New York, NY; ⁴Stanford University, Stanford, CA; ⁵21st Century Oncology, Fort Myers, FL; ⁶Phoenix Molecular Imaging, Phoenix, AZ; ⁷Dana-Farber Cancer Institute, Boston, MA; ⁸Massachusetts General Hospital, Boston, MA; ⁹Thomas Jefferson University, Philadelphia, PA; ¹⁰Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA; ¹¹Carolina Urologic Research Center, Myrtle Beach, SC; ¹²Bayer HealthCare Pharmaceuticals, Inc, Whippany, NJ; ¹³Comprehensive Cancer Centers of Nevada, Las Vegas, NV

BACKGROUND AND OBJECTIVE

Radium-223 Dichloride (Radium-223)

- First approved alpha-emitting radiopharmaceutical with a potent and highly targeted cytotoxic effect on bone metastases¹
- In the phase 3 ALSYMPCA trial, Radium-223 compared with placebo in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases²
 - Established efficacy with an overall survival (OS) benefit of 3.6 months (P < 0.001)
 - Had a favorable safety profile with low rates of myelosuppression

US Early Access Program (EAP)


- A phase 2, prospective, interventional, open-label, multicenter study was conducted in the United States to
 - Provide early access of radium-223 to patients with CRPC and symptomatic bone metastases prior to regulatory approval
 - Monitor acute and long-term safety of radium-223

- Radium-223 concurrently administered with abiraterone (Abi) or enzalutamide (Enza) was safe and well tolerated³
- The objective of this analysis is to explore the impact of prior Abi and/or Enza treatment on patient demographics, safety, and OS

METHODS

• US EAP eligibility criteria were similar to those of ALSYMPCA² (Figure 1)

Figure 1. US EAP Study Design



¹Regular use of opioid or nonopioid analgesics for cancer-related bone pain or external beam radiation therapy within 12 weeks prior to treatment.
²According to local clinical practice, if chemotherapy is considered best standard of care, radium-223 must be administered on the day of the last chemotherapy cycle.
³BRP is a Shared Pain Inventory-Short Form. CRPC = castration-resistant prostate cancer; EAP = Expanded Access Program; EOCG P5 = Eastern Cooperative Oncology Group performance status (P5); CRPC = castration-resistant prostate cancer; PSA = prostate-specific antigen; SAE = serious adverse events; SE = symptomatic skeletal events; TAE = total alkaline phosphatase; TEAE = treatment-emergent adverse event.

- Treatment period: time from first dose of study treatment through last dose + 30 days
- Follow-up was short (~3-9 mo) because of study termination due to commercial availability of radium-223
- Prior therapies: taken prior to and stopped at study entry; patient numbers were updated from the abstract
- Chi-square tests were done to assess differences in patient demographics and number of injections between prior-treatment subgroups
- Stepwise logistic regression analysis identified baseline covariates predictive of receiving 1-4 versus 5-6 injections of radium-223
 - Parameters examined: prior Abi and Enza, baseline albumin, baseline hemoglobin below normal, baseline log prostate-specific antigen (PSA), baseline log alkaline phosphatase (ALP), 3 or more prior anticancer medications, baseline Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2, and prior docetaxel
- All variables were analyzed primarily by descriptive statistics

RESULTS

Patients

- Of the 184 patients in EAP, 48 (26%) had prior Abi and Enza, 83 (45%) had prior Abi or Enza, and 53 (29%) were Abi and Enza naïve
- Patients with prior Abi and Enza had the greatest extent of disease based on ALP and PSA (Table 1)
- 83% of patients with prior Abi and Enza also had prior docetaxel treatment, compared with 30% of Abi- and Enza-naïve patients (Table 1)

Table 1. Demographics and Baseline Characteristics, by Prior Abiraterone and/or Enzalutamide


	Prior Abiraterone and Enzalutamide		Prior Abiraterone or Enzalutamide		Naïve (No Prior Abiraterone or Enzalutamide)	
	Yes	No	Yes	No	Yes	No
Age, median, y	70	70	71	69	69	71
Weight, median, kg	83	87	87	86	88	84
ECOG PS ≤ 1, n (%)	43 (90)	122 (90)	74 (88)	91 (90)	48 (91)	117 (89)
PSA, median, µg/L	220	159	146	129	107	172
ALP, median, U/L	215	137	147	162	130	159
Total ALP > 220 U/L, n (%)	23 (48)	33 (24)	23 (28)	33 (33)	10 (19)	46 (35)
Prior docetaxel, n (%)	40 (83)	70 (52)	54 (65)	56 (55)	16 (30)	94 (72)

ALP = alkaline phosphatase; ECOG PS = Eastern Cooperative Oncology Group performance status; PSA = prostate-specific antigen.

- Patients with prior Abi and Enza had a lower median number of injections (4) compared with those with prior Abi or Enza, and Abi- and Enza-naïve patients (5 and 6, respectively)
- Patients with prior Abi and Enza had a significantly lower percentage of patients completing 5-6 injections, compared with those without prior Abi and Enza (35% vs 60%; P = 0.003) (Figure 2)

- A significantly greater percentage of Abi- and Enza-naïve patients received all 6 injections, compared with patients who had prior Abi and Enza (57% vs 29%; P = 0.006) (Figure 2)


Figure 2. Number of Injections Received, by Prior Abiraterone and/or Enzalutamide



Logistic Regression Analysis

- Baseline covariates predicting receipt of 1-4 versus 5-6 radium-223 injections were prior Abi and Enza (P = 0.0141), baseline ECOG PS ≥ 2 (P = 0.0202), and baseline hemoglobin below normal (P = 0.0042); prior docetaxel was nearly significant (P = 0.0501) (Figure 3)

Figure 3. Logistic Regression ROC Curves



Abi = abiraterone; AUC = area under the curve; ECOG PS = Eastern Cooperative Oncology Group performance status; Enza = enzalutamide; ROC = receiver operating characteristic.

Safety

- Safety profiles were comparable across prior-treatment subgroups (Table 2)

Table 2. Summary of AE Categories, by Prior Abiraterone and/or Enzalutamide


	Prior Abiraterone and Enzalutamide		Prior Abiraterone or Enzalutamide		Naïve (No Prior Abiraterone or Enzalutamide)	
	Yes	No	Yes	No	Yes	No
Grade 3-4 TEAE	n = 48	n = 136	n = 83	n = 101	n = 53	n = 131
Treatment-related TEAE	25 (52)	48 (50)	45 (54)	48 (48)	23 (43)	70 (53)
Serious AE	15 (31)	30 (22)	19 (23)	26 (26)	11 (21)	34 (26)
Discontinuation due to TEAE	9 (19)	21 (15)	15 (18)	15 (15)	6 (11)	24 (18)

AE = adverse event; TEAE = treatment-emergent AE.

OS: Prior Abiraterone and/or Enzalutamide

- Median OS of patients with either prior Abi or Enza was similar to that of the overall EAP population, 15.6 versus 17 months, respectively (Figure 4 B and D), and
 - Patients with prior Abi and Enza had a shorter median OS (10.7 mo) (Figure 4 A and C)
- Median OS of Abi- and Enza-naïve patients was not estimable due to short follow-up time and patient censoring, appearing longer than that of patients with prior treatment (Figure 4 C and E)

Figure 4. Overall Survival, by Prior Abiraterone and/or Enzalutamide




Abi = abiraterone; EAP = Expanded Access Program; Enza = enzalutamide; NE = not estimable due to a short follow-up time and large percentage of patients in the overall population (29%) censored at the time of analysis.

OS: Number of Radium-223 Injections

- Because a greater percentage of Abi- and Enza-naïve patients received all 6 injections (57%) and appeared to have longer OS, survival was analyzed by number of radium-223 injections received
 - Median OS of patients receiving 5-6 radium-223 injections (54%) trended longer than that of patients receiving 1-4 injections (46%) (Figure 5A)
 - In the overall EAP population, median OS was 17 months (Figure 5B) and 44% of patients received all 6 radium-223 injections (median, 5 injections)

Figure 5. Overall Survival, by Number of Radium-223 Injections



EAP = Expanded Access Program; NE = not estimable due to a short follow-up time and large percentage of patients in the overall population (29%) censored at the time of analysis.

CONCLUSIONS

- In this EAP, radium-223 was safe and well tolerated regardless of prior Abi and/or Enza treatment
- A trend was observed: patients with less prior treatment were more likely to complete 5-6 radium-223 injections
- Baseline covariates predictive of receiving only 1-4 versus 5-6 injections were prior Abi and Enza, ECOG PS ≥ 2, and decreased baseline hemoglobin
- Prolonged OS was associated with receiving 5-6 versus 1-4 radium-223 injections, a finding that requires further validation
- Using radium-223 later in the current sequencing paradigm may limit the number of patients able to receive 6 cycles of treatment, as recommended in the radium-223 label

REFERENCES

- Xofigo (radium Ra 223 dichloride) injection, for intravenous use [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2013.
- Parker et al. *N Engl J Med.* 2013;369:213-223.
- Sartor et al. *J Clin Oncol.* 2015;33(suppl 7): Abstract 253.

Acknowledgments

This study was supported by Bayer HealthCare Pharmaceuticals, Inc. The authors wish to thank SciStrategy Communications for editorial and creative assistance in the preparation of this poster.



Copyright © 2015 by ASCO. All rights reserved. This poster was prepared and published by ASCO and the authors of this poster.

Abstract 5063

¹Tulane Cancer Center, New Orleans, LA; ²Thomas Jefferson University, Philadelphia, PA


BACKGROUND AND OBJECTIVES

- Radium-223 Dichloride (Radium-223)**
- First approved alpha-emitting radiopharmaceutical with highly targeted cytotoxic effect on bone metastases
 - In the phase 3 ALSYMPCA trial, radium-223 c in patients with castration-resistant prostate cancer with symptomatic bone metastases¹
 - Established efficacy with an overall survival (P < 0.001)
 - Had a favorable safety profile with low rate of adverse events
- US Early Access Program (EAP)**
- A phase 2, prospective, interventional, open-label study was conducted in the United States to provide early access to radium-223 to patients with symptomatic bone metastases prior to registration
 - Monitor acute and long-term safety of radium-223 concurrently administered with enzalutamide (Enza) was safe and well tolerated
 - The objective of this analysis is to explore the safety and efficacy of radium-223 in patients with prior Abi and/or Enza treatment on patient demographic

METHODS

- US EAP eligibility criteria were similar to those of the ALSYMPCA trial

Figure 1. US EAP Study Design



*Regular use of opioid or nonopioid analgesics for cancer-related bone pain 12 weeks prior to treatment
 †According to local clinical practice, if chemotherapy is considered best standard of care

CRPC = castration-resistant prostate cancer; EAP = Expanded Access Program; OS = overall survival; PSA = prostate-specific antigen; TEAE = treatment-emergent adverse event; PSA-adj = total alkaline phosphatase; PSA-adj = treatment-emergent adverse events.

- Patients with prior Abi and Enza had a significantly lower percentage of patients completing 5-6 injections, compared with those without prior Abi and Enza (35% vs 60%; P = 0.003) (Figure 2)

CONCLUSIONS

- In this EAP, radium-223 was safe and well tolerated regardless of prior Abi and/or Enza treatment
- A trend was observed: patients with less prior treatment were more likely to complete 5-6 radium-223 injections
- Baseline covariates predictive of receiving only 1-4 versus 5-6 injections were prior Abi and Enza, ECOG PS ≥ 2, and decreased baseline hemoglobin
- Prolonged OS was associated with receiving 5-6 versus 1-4 radium-223 injections, a finding that requires further validation
- Using radium-223 later in the current sequencing paradigm may limit the number of patients able to receive 6 cycles of treatment, as recommended in the radium-223 label

Treatment-related TEAE	25 (52)	68 (50)	45 (54)	48 (60)	23 (43)	70 (53)
Serious AE	15 (31)	30 (22)	19 (23)	26 (32)	11 (21)	34 (26)
Discontinuation due to TEAE	9 (19)	21 (15)	15 (18)	15 (19)	6 (11)	24 (18)

AE = adverse event; TEAE = treatment-emergent AE

EAP = Expanded Access Program; NE = not estimable due to a short follow-up time and large percentage of patients in the overall population (50%) still alive at the time of analysis.

Program Setting


Matthew R. Smith,⁸ Adam P. Dicker,⁹ and Michael J. Zele,¹⁰ et al.

¹University of Pennsylvania, Philadelphia, PA; ²University of California, San Francisco, CA; ³University of Michigan, Ann Arbor, MI; ⁴Dana-Farber Cancer Institute, Boston, MA; ⁵Massachusetts General Hospital, Boston, MA; ⁶University of Texas MD Anderson Cancer Center, Houston, TX; ⁷University of Colorado, Denver, CO; ⁸University of Colorado, Denver, CO; ⁹University of Colorado, Denver, CO; ¹⁰University of Colorado, Denver, CO

Enzalutamide

Abiraterone or Enza was similar to that of Enza (10.7 months, respectively) in patients with less prior treatment. OS was not estimable due to a short follow-up time and large percentage of patients in the overall population (50%) still alive at the time of analysis.


Enzalutamide or Enzalutamide



Enza-naïve

Enza-naïve patients received a median of 5.6 injections (54% trended to receive 1-4 injections (46%) (Figure 5A)). OS was 17 months (median, 10.7 months).

Radium-223 Injections



CONCLUSIONS

- In this EAP, radium-223 was safe and well tolerated regardless of prior Abi and/or Enza treatment
- A trend was observed: patients with less prior treatment were more likely to complete 5-6 radium-223 injections
- Baseline covariates predictive of receiving only 1-4 versus 5-6 injections were prior Abi and Enza, ECOG PS ≥ 2, and decreased baseline hemoglobin
- Prolonged OS was associated with receiving 5-6 versus 1-4 radium-223 injections, a finding that requires further validation
- Using radium-223 later in the current sequencing paradigm may limit the number of patients able to receive 6 cycles of treatment, as recommended in the radium-223 label

REFERENCES

1. Xofigo (radium Ra 223 dichloride) injection, for intravenous use (package insert). Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2013.
2. Parker et al. *N Engl J Med.* 2013;369:227-233.
3. Sartor et al. *J Clin Oncol.* 2015;33(suppl 7). Abstract 253.

Acknowledgments


This study was supported by Bayer HealthCare Pharmaceuticals, Inc. The authors wish to thank SciStrategy Communications for editorial and creative assistance in the preparation of this poster.



Copyright © 2015, American Society of Clinical Oncology. All rights reserved. This poster is a reproduction of the original poster presented at ASCO 2015. For more information, please visit www.asco.org.

Study Design

Phase 2, prospective, interventional, open-label, multicenter study
EAP (15995)



*Regular use of any analgesic or EBRT within 12 weeks prior to treatment.

†According to local clinical practice. If chemo/radiotherapy is considered best standard of care, radium 223 must be discontinued.

Select Prior Systemic Anticancer Therapy (≥5 Patients)^a

Hormone and Hormone-Related Agents (N=184)	n
Bicalutamide	147
Leuprolide acetate	111
Abiraterone	120 (65%)
Enzalutamide	59 (32%)
Prednisone	47
Diethylstilbestrol	24
Nilutamide	21
Goserelin	21
Flutamide	21
Nilandron	18
Triptorelin pamoate	17
Luteinizing hormone–releasing hormone	14
Degarelix acetate	13
Dutasteride	12
Estrogen	7

^aA patient could have had >1 medication.

Summary of TEAEs

	US EAP ^a (N=184)	
	n	(%)
Number of patients with at ≥1 TEAE	133	(72)
Grade 3	58	(32)
Grade 4	9	(5)
Grade 5 (death)	8	(4)
Any serious TEAE	45	(25)
TEAEs leading to dose modifications, ^a delay ^b	18	(10)
TEAEs leading to permanent discontinuation	30	(16)
Number of patients with any related TEAE	93	(51)
Grade 3	23	(13)
Grade 4	6	(3)
Grade 5 (death)	0	
Any serious related TEAEs	11	(6)
Related leading to dose modifications	13	(7)
Related leading to permanent discontinuation	16	(9)

TEAE: Treatment Emergent Adverse Events.

Total Number of Injections Received by Patients

Number of Patients Receiving Injections	US EAP ^a (N=184)	
	n	(%)
1 injection	6	(3)
2 injections	26	(14)
3 injections	27	(15)
4 injections	26	(14)
5 injections	18	(10)
6 injections	81	(44)
Mean number of injections	4.5	

^aSafety analysis set.


TEAEs of Interest

Event Term	US EAP ^a (N=184)							
	Any Grade		Grade 3		Grade 4		Grade 5	
	n	(%)	n	(%)	n	(%)	n	(%)
Blood and lymphatic system	32	(17)	11	(6)	3	(2)	0	
Anemia	29	(16)	10	(5)	1	(1)	0	
Thrombocytopenia	9	(5)	2	(1)	2	(1)	0	
Leukopenia	1	(1)	1	(1)	0		0	
Neutropenia	3	(2)	2	(1)	0		0	
Gastrointestinal disorders	42	(23)	2	(1)	1	(1)	0	
Diarrhea	23	(13)	1	(1)	0		0	
Gastric ulcer	1	(1)	1	(1)	0		0	
Rectal hemorrhage	1	(1)	1	(1)	0		0	
Upper GI hemorrhage	1	(1)	0		1	(1)	0	

^aSafety analysis set

US EAP EXPLORATORY EFFICACY ANALYSES

Exploratory Analyses: Maximum Percentage Decline in ALP by Patient



**SUBGROUP ANALYSES OF EFFICACY:
CONCOMITANT BLOCKADE OF
ANDROGEN SIGNALING AXIS AND
RADIUM 223 IN US EAP**

Subgroup Analysis: Concurrent Abiraterone Use

	Not Concurrent With Abiraterone (n=159)	Concurrent With Abiraterone (n=25)
Age, median (y)	72	66
Race n (%)		
White	147 (93)	22 (88)
African American	6 (4)	1 (4)
Asian	2 (1.3)	2 (8)
Not reported	4 (3)	0
Weight, median (kg)	86	86
ECOG PS ≤1, n (%)	140 (88)	25 (100)
Total ALP ≥220 U/L, n (%)	48 (30)	8 (32)
Current use of bisphosphonates (yes), n (%)	12 (8)	5 (20)
Prior use of docetaxel, n (%)	99 (62)	11 (44)
Pain at baseline, n (%)		
No pain	5 (3)	1 (4)
Mild to moderate	79 (50)	8 (32)
Severe	30 (19)	5 (20)
Missing	45 (28)	11 (44)


Grade 3 to 5 TEAEs of Interest: Concurrent Abiraterone Use

During Treatment Period		
	Not Concurrent With Abiraterone (n=159)	Concurrent With Abiraterone (n=25)
TEAEs		
Hematologic, n (%)		
Anemia	17 (11)	4 (16) (12 vs 13% in ROW)
Neutropenia	2 (1)	0 (0) (1% in each)
Thrombocytopenia	4 (3)	1 (4) (3 vs 1% in ROW)
Nonhematologic, n (%)		
Diarrhea	0 (0)	1 (4) (<1% each in ROW)
Fatigue	4 (3)	0 (0)
Bone pain	4 (3)	0 (0)

Exploratory Analyses: OS by Current Use of Abiraterone

	n (%) of Patients With Event		n (%) of Patients Censored		Median Time to First Event, mo (95% CI)	
	Yes	No	Yes	No	Yes	No
OS	7 (20)	43 (29)	28 (80)	106 (71)	NA (A, A)	16 (9, A)

A, value cannot be estimated due to censored data.



Patients at risk

Yes	35	28	4	2	0
No	149	75	11	2	0


Grade 3 to 5 TEAEs of Interest: Concurrent Enzalutamide Use

	During Treatment Period	
	Not Concurrent With Enzalutamide (n=169)	Concurrent With Enzalutamide (n=15)
TEAEs		
Hematologic, n (%)		
Anemia	19 (11)	2 (13)
Neutropenia	2 (1)	0 (0)
Thrombocytopenia	5 (3)	0 (0)
Nonhematologic, n (%)		
Diarrhea	1 (1)	0 (0)
Fatigue	4 (2)	0 (0)
Bone pain	4 (2)	0 (0)

Exploratory Analyses: OS by Current Use of Enzalutamide

	n (%) of Patients With Event		n (%) of Patients Censored		Median Time to First Event, mo (95% CI)	
	Yes	No	Yes	No	Yes	No
OS	6 (24)	44 (27)	19 (76)	115 (72)	NA (11, A)	17 (10, A)

A, value cannot be estimated due to censored data.



Saad F, et al. Radium-223 in an International Early Access Program (EAP): Effects of Concomitant Medication on Overall Survival in mCRPC (ASCO 2015, Abstract 5063)

Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients

Fred Saad¹, Joan Carles², Silke Gillesen³, Daniel Heinrich⁴, Jeremy Gratt⁵, Kurt Miller⁶, Sten Nilsson⁷, Joe O'Sullivan⁸, Marcello Tucci⁹, Manfred Wirth¹⁰, Axel Heidenreich¹¹

¹University of Montreal Hospital Centers, Montreal, Canada; ²Wall of Hebron University Hospital, Wall of Hebron Institute of Oncology, Barcelona, Spain; ³Kantonsspital St Gallen, St Gallen, Switzerland; ⁴Akershus University Hospital, Lørenskog, Norway; ⁵Bayer Healthcare Pharmaceuticals, Whippany New Jersey, US; ⁶Charité University Medicine Berlin, Berlin, Germany; ⁷Karolinska University Hospital, Stockholm, Sweden; ⁸Centre for Cancer Research and Cell Biology, Queen's University Belfast, and the Northern Ireland Cancer Centre, Belfast, Northern Ireland; ⁹Department of Oncology, San Luigi Hospital, Orbassano (Turin) Italy; ¹⁰University Hospital Carl-Neuberg, Dresden, Germany; ¹¹University Hospital, RWTH Aachen, Aachen, Germany

Abstract 5034

BACKGROUND

- Radium-223 dichloride (Ra-223) is the first α -particle emitting bone-targeting agent approved for use in mCRPC patients with bone metastases and no known visceral metastases.
- In the pivotal ALSYMPCA study¹ treating mCRPC patients with symptomatic bone metastases with Ra-223 and best standard of care (BSOC) compared with placebo and BSOC:
 - Improved overall survival (OS, median 14.9 vs 11.3 months, hazard ratio=0.70; p<0.001)
 - Delayed time to first symptomatic skeletal event (SSEF)
 - Was generally well tolerated with minimal hematological toxicity reported.
- Safety and efficacy data of Ra-223 are presented from an EAP in which Ra-223 was administered to patients enrolled from sites in Canada, Europe, and Israel.


STUDY OBJECTIVES

- Primary outcome measures were safety and OS.
- Planned exploratory analyses included:
 - Time to first skeletal related event (SRE)
 - Changes in total alkaline phosphatase (ALP) activity and prostate specific antigen (PSA) levels from baseline
 - Time to ALP/PSA progression.
- Post hoc analyses included OS in subgroups based on:
 - Concomitant medication at baseline (abiraterone, enzalutamide, docetaxel, denosumab and bisphosphonates)
 - Baseline total ALP values
 - Baseline Eastern Cooperative Oncology Group performance status (ECOG PS)
 - Baseline pain.

PATIENTS AND METHODS

- This was a phase 3b, international, prospective, interventional, open-label, multicenter EAP (Figure 1).
- Eligibility criteria were generally similar to those in the ALSYMPCA study with the exception that asymptomatic patients were allowed in the EAP.
- Analysis of variables was by descriptive statistics.
- The study was terminated on regulatory approval of Ra-223. Follow-up was 30 days from the last patient treated.

Figure 1. Study design



*BSOC: according to local clinical practice. If chemotherapy/palliative care is considered BSOC. Ra-223 must be discontinued. †Adverse events were coded according to MedDRA version 17.1 and graded by NCI CTCAE version 4.0. ALP=alkaline phosphatase; CRPC=castration-resistant prostate cancer; BSOC=best standard of care; EAP=early access program; EOC=Eastern Cooperative Oncology Group performance status; MedDRA=medical dictionary for regulatory activities; mCRPC=metastatic castration-resistant prostate cancer; PSA=prostate specific antigen; OS=overall survival; SSEF=every 6 weeks; SSEF 24=every 24 hours; SSEF 48=every 48 hours; SSEF 72=every 72 hours; SSEF 96=every 96 hours; SSEF 120=every 120 hours; SSEF 144=every 144 hours; SSEF 168=every 168 hours; SSEF 192=every 192 hours; SSEF 216=every 216 hours; SSEF 240=every 240 hours; SSEF 264=every 264 hours; SSEF 288=every 288 hours; SSEF 312=every 312 hours; SSEF 336=every 336 hours; SSEF 360=every 360 hours; SSEF 384=every 384 hours; SSEF 408=every 408 hours; SSEF 432=every 432 hours; SSEF 456=every 456 hours; SSEF 480=every 480 hours; SSEF 504=every 504 hours; SSEF 528=every 528 hours; SSEF 552=every 552 hours; SSEF 576=every 576 hours; SSEF 600=every 600 hours; SSEF 624=every 624 hours; SSEF 648=every 648 hours; SSEF 672=every 672 hours; SSEF 696=every 696 hours; SSEF 720=every 720 hours; SSEF 744=every 744 hours; SSEF 768=every 768 hours; SSEF 792=every 792 hours; SSEF 816=every 816 hours; SSEF 840=every 840 hours; SSEF 864=every 864 hours; SSEF 888=every 888 hours; SSEF 912=every 912 hours; SSEF 936=every 936 hours; SSEF 960=every 960 hours; SSEF 984=every 984 hours; SSEF 1008=every 1008 hours; SSEF 1032=every 1032 hours; SSEF 1056=every 1056 hours; SSEF 1080=every 1080 hours; SSEF 1104=every 1104 hours; SSEF 1128=every 1128 hours; SSEF 1152=every 1152 hours; SSEF 1176=every 1176 hours; SSEF 1200=every 1200 hours; SSEF 1224=every 1224 hours; SSEF 1248=every 1248 hours; SSEF 1272=every 1272 hours; SSEF 1296=every 1296 hours; SSEF 1320=every 1320 hours; SSEF 1344=every 1344 hours; SSEF 1368=every 1368 hours; SSEF 1392=every 1392 hours; SSEF 1416=every 1416 hours; SSEF 1440=every 1440 hours; SSEF 1464=every 1464 hours; SSEF 1488=every 1488 hours; SSEF 1512=every 1512 hours; SSEF 1536=every 1536 hours; SSEF 1560=every 1560 hours; SSEF 1584=every 1584 hours; SSEF 1608=every 1608 hours; SSEF 1632=every 1632 hours; SSEF 1656=every 1656 hours; SSEF 1680=every 1680 hours; SSEF 1704=every 1704 hours; SSEF 1728=every 1728 hours; SSEF 1752=every 1752 hours; SSEF 1776=every 1776 hours; SSEF 1800=every 1800 hours; SSEF 1824=every 1824 hours; SSEF 1848=every 1848 hours; SSEF 1872=every 1872 hours; SSEF 1896=every 1896 hours; SSEF 1920=every 1920 hours; SSEF 1944=every 1944 hours; SSEF 1968=every 1968 hours; SSEF 1992=every 1992 hours; SSEF 2016=every 2016 hours; SSEF 2040=every 2040 hours; SSEF 2064=every 2064 hours; SSEF 2088=every 2088 hours; SSEF 2112=every 2112 hours; SSEF 2136=every 2136 hours; SSEF 2160=every 2160 hours; SSEF 2184=every 2184 hours; SSEF 2208=every 2208 hours; SSEF 2232=every 2232 hours; SSEF 2256=every 2256 hours; SSEF 2280=every 2280 hours; SSEF 2304=every 2304 hours; SSEF 2328=every 2328 hours; SSEF 2352=every 2352 hours; SSEF 2376=every 2376 hours; SSEF 2400=every 2400 hours; SSEF 2424=every 2424 hours; SSEF 2448=every 2448 hours; SSEF 2472=every 2472 hours; SSEF 2496=every 2496 hours; SSEF 2520=every 2520 hours; SSEF 2544=every 2544 hours; SSEF 2568=every 2568 hours; SSEF 2592=every 2592 hours; SSEF 2616=every 2616 hours; SSEF 2640=every 2640 hours; SSEF 2664=every 2664 hours; SSEF 2688=every 2688 hours; SSEF 2712=every 2712 hours; SSEF 2736=every 2736 hours; SSEF 2760=every 2760 hours; SSEF 2784=every 2784 hours; SSEF 2808=every 2808 hours; SSEF 2832=every 2832 hours; SSEF 2856=every 2856 hours; SSEF 2880=every 2880 hours; SSEF 2904=every 2904 hours; SSEF 2928=every 2928 hours; SSEF 2952=every 2952 hours; SSEF 2976=every 2976 hours; SSEF 3000=every 3000 hours; SSEF 3024=every 3024 hours; SSEF 3048=every 3048 hours; SSEF 3072=every 3072 hours; SSEF 3096=every 3096 hours; SSEF 3120=every 3120 hours; SSEF 3144=every 3144 hours; SSEF 3168=every 3168 hours; SSEF 3192=every 3192 hours; SSEF 3216=every 3216 hours; SSEF 3240=every 3240 hours; SSEF 3264=every 3264 hours; SSEF 3288=every 3288 hours; SSEF 3312=every 3312 hours; SSEF 3336=every 3336 hours; SSEF 3360=every 3360 hours; SSEF 3384=every 3384 hours; SSEF 3408=every 3408 hours; SSEF 3432=every 3432 hours; SSEF 3456=every 3456 hours; SSEF 3480=every 3480 hours; SSEF 3504=every 3504 hours; SSEF 3528=every 3528 hours; SSEF 3552=every 3552 hours; SSEF 3576=every 3576 hours; SSEF 3600=every 3600 hours; SSEF 3624=every 3624 hours; SSEF 3648=every 3648 hours; SSEF 3672=every 3672 hours; SSEF 3696=every 3696 hours; SSEF 3720=every 3720 hours; SSEF 3744=every 3744 hours; SSEF 3768=every 3768 hours; SSEF 3792=every 3792 hours; SSEF 3816=every 3816 hours; SSEF 3840=every 3840 hours; SSEF 3864=every 3864 hours; SSEF 3888=every 3888 hours; SSEF 3912=every 3912 hours; SSEF 3936=every 3936 hours; SSEF 3960=every 3960 hours; SSEF 3984=every 3984 hours; SSEF 4008=every 4008 hours; SSEF 4032=every 4032 hours; SSEF 4056=every 4056 hours; SSEF 4080=every 4080 hours; SSEF 4104=every 4104 hours; SSEF 4128=every 4128 hours; SSEF 4152=every 4152 hours; SSEF 4176=every 4176 hours; SSEF 4200=every 4200 hours; SSEF 4224=every 4224 hours; SSEF 4248=every 4248 hours; SSEF 4272=every 4272 hours; SSEF 4296=every 4296 hours; SSEF 4320=every 4320 hours; SSEF 4344=every 4344 hours; SSEF 4368=every 4368 hours; SSEF 4392=every 4392 hours; SSEF 4416=every 4416 hours; SSEF 4440=every 4440 hours; SSEF 4464=every 4464 hours; SSEF 4488=every 4488 hours; SSEF 4512=every 4512 hours; SSEF 4536=every 4536 hours; SSEF 4560=every 4560 hours; SSEF 4584=every 4584 hours; SSEF 4608=every 4608 hours; SSEF 4632=every 4632 hours; SSEF 4656=every 4656 hours; SSEF 4680=every 4680 hours; SSEF 4704=every 4704 hours; SSEF 4728=every 4728 hours; SSEF 4752=every 4752 hours; SSEF 4776=every 4776 hours; SSEF 4800=every 4800 hours; SSEF 4824=every 4824 hours; SSEF 4848=every 4848 hours; SSEF 4872=every 4872 hours; SSEF 4896=every 4896 hours; SSEF 4920=every 4920 hours; SSEF 4944=every 4944 hours; SSEF 4968=every 4968 hours; SSEF 4992=every 4992 hours; SSEF 5016=every 5016 hours; SSEF 5040=every 5040 hours; SSEF 5064=every 5064 hours; SSEF 5088=every 5088 hours; SSEF 5112=every 5112 hours; SSEF 5136=every 5136 hours; SSEF 5160=every 5160 hours; SSEF 5184=every 5184 hours; SSEF 5208=every 5208 hours; SSEF 5232=every 5232 hours; SSEF 5256=every 5256 hours; SSEF 5280=every 5280 hours; SSEF 5304=every 5304 hours; SSEF 5328=every 5328 hours; SSEF 5352=every 5352 hours; SSEF 5376=every 5376 hours; SSEF 5400=every 5400 hours; SSEF 5424=every 5424 hours; SSEF 5448=every 5448 hours; SSEF 5472=every 5472 hours; SSEF 5496=every 5496 hours; SSEF 5520=every 5520 hours; SSEF 5544=every 5544 hours; SSEF 5568=every 5568 hours; SSEF 5592=every 5592 hours; SSEF 5616=every 5616 hours; SSEF 5640=every 5640 hours; SSEF 5664=every 5664 hours; SSEF 5688=every 5688 hours; SSEF 5712=every 5712 hours; SSEF 5736=every 5736 hours; SSEF 5760=every 5760 hours; SSEF 5784=every 5784 hours; SSEF 5808=every 5808 hours; SSEF 5832=every 5832 hours; SSEF 5856=every 5856 hours; SSEF 5880=every 5880 hours; SSEF 5904=every 5904 hours; SSEF 5928=every 5928 hours; SSEF 5952=every 5952 hours; SSEF 5976=every 5976 hours; SSEF 6000=every 6000 hours; SSEF 6024=every 6024 hours; SSEF 6048=every 6048 hours; SSEF 6072=every 6072 hours; SSEF 6096=every 6096 hours; SSEF 6120=every 6120 hours; SSEF 6144=every 6144 hours; SSEF 6168=every 6168 hours; SSEF 6192=every 6192 hours; SSEF 6216=every 6216 hours; SSEF 6240=every 6240 hours; SSEF 6264=every 6264 hours; SSEF 6288=every 6288 hours; SSEF 6312=every 6312 hours; SSEF 6336=every 6336 hours; SSEF 6360=every 6360 hours; SSEF 6384=every 6384 hours; SSEF 6408=every 6408 hours; SSEF 6432=every 6432 hours; SSEF 6456=every 6456 hours; SSEF 6480=every 6480 hours; SSEF 6504=every 6504 hours; SSEF 6528=every 6528 hours; SSEF 6552=every 6552 hours; SSEF 6576=every 6576 hours; SSEF 6600=every 6600 hours; SSEF 6624=every 6624 hours; SSEF 6648=every 6648 hours; SSEF 6672=every 6672 hours; SSEF 6696=every 6696 hours; SSEF 6720=every 6720 hours; SSEF 6744=every 6744 hours; SSEF 6768=every 6768 hours; SSEF 6792=every 6792 hours; SSEF 6816=every 6816 hours; SSEF 6840=every 6840 hours; SSEF 6864=every 6864 hours; SSEF 6888=every 6888 hours; SSEF 6912=every 6912 hours; SSEF 6936=every 6936 hours; SSEF 6960=every 6960 hours; SSEF 6984=every 6984 hours; SSEF 7008=every 7008 hours; SSEF 7032=every 7032 hours; SSEF 7056=every 7056 hours; SSEF 7080=every 7080 hours; SSEF 7104=every 7104 hours; SSEF 7128=every 7128 hours; SSEF 7152=every 7152 hours; SSEF 7176=every 7176 hours; SSEF 7200=every 7200 hours; SSEF 7224=every 7224 hours; SSEF 7248=every 7248 hours; SSEF 7272=every 7272 hours; SSEF 7296=every 7296 hours; SSEF 7320=every 7320 hours; SSEF 7344=every 7344 hours; SSEF 7368=every 7368 hours; SSEF 7392=every 7392 hours; SSEF 7416=every 7416 hours; SSEF 7440=every 7440 hours; SSEF 7464=every 7464 hours; SSEF 7488=every 7488 hours; SSEF 7512=every 7512 hours; SSEF 7536=every 7536 hours; SSEF 7560=every 7560 hours; SSEF 7584=every 7584 hours; SSEF 7608=every 7608 hours; SSEF 7632=every 7632 hours; SSEF 7656=every 7656 hours; SSEF 7680=every 7680 hours; SSEF 7704=every 7704 hours; SSEF 7728=every 7728 hours; SSEF 7752=every 7752 hours; SSEF 7776=every 7776 hours; SSEF 7800=every 7800 hours; SSEF 7824=every 7824 hours; SSEF 7848=every 7848 hours; SSEF 7872=every 7872 hours; SSEF 7896=every 7896 hours; SSEF 7920=every 7920 hours; SSEF 7944=every 7944 hours; SSEF 7968=every 7968 hours; SSEF 7992=every 7992 hours; SSEF 8016=every 8016 hours; SSEF 8040=every 8040 hours; SSEF 8064=every 8064 hours; SSEF 8088=every 8088 hours; SSEF 8112=every 8112 hours; SSEF 8136=every 8136 hours; SSEF 8160=every 8160 hours; SSEF 8184=every 8184 hours; SSEF 8208=every 8208 hours; SSEF 8232=every 8232 hours; SSEF 8256=every 8256 hours; SSEF 8280=every 8280 hours; SSEF 8304=every 8304 hours; SSEF 8328=every 8328 hours; SSEF 8352=every 8352 hours; SSEF 8376=every 8376 hours; SSEF 8400=every 8400 hours; SSEF 8424=every 8424 hours; SSEF 8448=every 8448 hours; SSEF 8472=every 8472 hours; SSEF 8496=every 8496 hours; SSEF 8520=every 8520 hours; SSEF 8544=every 8544 hours; SSEF 8568=every 8568 hours; SSEF 8592=every 8592 hours; SSEF 8616=every 8616 hours; SSEF 8640=every 8640 hours; SSEF 8664=every 8664 hours; SSEF 8688=every 8688 hours; SSEF 8712=every 8712 hours; SSEF 8736=every 8736 hours; SSEF 8760=every 8760 hours; SSEF 8784=every 8784 hours; SSEF 8808=every 8808 hours; SSEF 8832=every 8832 hours; SSEF 8856=every 8856 hours; SSEF 8880=every 8880 hours; SSEF 8904=every 8904 hours; SSEF 8928=every 8928 hours; SSEF 8952=every 8952 hours; SSEF 8976=every 8976 hours; SSEF 9000=every 9000 hours; SSEF 9024=every 9024 hours; SSEF 9048=every 9048 hours; SSEF 9072=every 9072 hours; SSEF 9096=every 9096 hours; SSEF 9120=every 9120 hours; SSEF 9144=every 9144 hours; SSEF 9168=every 9168 hours; SSEF 9192=every 9192 hours; SSEF 9216=every 9216 hours; SSEF 9240=every 9240 hours; SSEF 9264=every 9264 hours; SSEF 9288=every 9288 hours; SSEF 9312=every 9312 hours; SSEF 9336=every 9336 hours; SSEF 9360=every 9360 hours; SSEF 9384=every 9384 hours; SSEF 9408=every 9408 hours; SSEF 9432=every 9432 hours; SSEF 9456=every 9456 hours; SSEF 9480=every 9480 hours; SSEF 9504=every 9504 hours; SSEF 9528=every 9528 hours; SSEF 9552=every 9552 hours; SSEF 9576=every 9576 hours; SSEF 9600=every 9600 hours; SSEF 9624=every 9624 hours; SSEF 9648=every 9648 hours; SSEF 9672=every 9672 hours; SSEF 9696=every 9696 hours; SSEF 9720=every 9720 hours; SSEF 9744=every 9744 hours; SSEF 9768=every 9768 hours; SSEF 9792=every 9792 hours; SSEF 9816=every 9816 hours; SSEF 9840=every 9840 hours; SSEF 9864=every 9864 hours; SSEF 9888=every 9888 hours; SSEF 9912=every 9912 hours; SSEF 9936=every 9936 hours; SSEF 9960=every 9960 hours; SSEF 9984=every 9984 hours; SSEF 10000=every 10000 hours.

RESULTS

- #### Patients
- 839 patients were enrolled from 113 sites in 14 countries, of which 696 were treated with >1 dose of Ra-223 (safety population, Figure 2).
 - Baseline characteristics in the EAP were generally similar to those for patients treated in the ALSYMPCA study except for pain at baseline and prior and concurrent treatment (Table 1).




Figure 2. Patient disposition in the Ra-223 EAP

Table 1. Patient baseline characteristics

Characteristic	EAP N=696	ALSYMPCA N=614*
Age, years		
Median (range)	72 (45-94)	71 (46-90)
>85	595 (81)	496 (74)
Median weight, kg (range)	81 (46-155)	82 (40-139)
ECOG PS \leq 1	609 (88)	536 (87)
Gleason score at diagnosis		
3-4	16 (2)	7 (1)
5-7	288 (29)	274 (45)
8-10	350 (50)	261 (42)
Missing	62 (9)	72 (12)
Median time since PC diagnosis, mos (range)	16 (0-52)	19 (0-42)
<6	10 (1)	10 (2)
6-12	34 (5)	28 (4)
12-24	261 (37)	241 (39)
24-36	261 (37)	241 (39)
>36	101 (15)	86 (14)
Median PSA, μ g/L (range)	141 (0-1215)	140 (33-602)
ALP		
<220 U/L	421 (60)	340 (55)
≥220 U/L	263 (38)	266 (43)
Missing	2 (0.3)	0
Pain at baseline†		
None	146 (21)	12 (2)
Mild-moderate	200 (29)	454 (74)
Severe	152 (22)	154 (25)
Missing	27 (4)	0
Prior use of docetaxel	416 (60)	352 (57)
Concomitant use of		
Biphosphonates	122 (18)	250 (41)
Denosumab	138 (20)	NA
Abiraterone	156 (23)	NA
Enzalutamide	30 (4)	NA
Prior radiotherapy	480 (70)	396 (64)
Prior systemic anticancer therapy	677 (97)	NA

Data are n (%). NA=not applicable; PC=prostate cancer; PSA=prostate specific antigen; ALP=alkaline phosphatase; BSOC=best standard of care; CRPC=castration-resistant prostate cancer; BSOC=best standard of care; EAP=early access program; EOC=Eastern Cooperative Oncology Group performance status; MedDRA=medical dictionary for regulatory activities; mCRPC=metastatic castration-resistant prostate cancer; PSA=prostate specific antigen; OS=overall survival; SSEF=every 6 weeks; SSEF 24=every 24 hours; SSEF 48=every 48 hours; SSEF 72=every 72 hours; SSEF 96=every 96 hours; SSEF 120=every 120 hours; SSEF 144=every 144 hours; SSEF 168=every 168 hours; SSEF 192=every 192 hours; SSEF 216=every 216 hours; SSEF 240=every 240 hours; SSEF 264=every 264 hours; SSEF 288=every 288 hours; SSEF 312=every 312 hours; SSEF 336=every 336 hours; SSEF 360=every 360 hours; SSEF 384=every 384 hours; SSEF 408=every 408 hours; SSEF 432=every 432 hours; SSEF 456=every 456 hours; SSEF 480=every 480 hours; SSEF 504=every 504 hours; SSEF 528=every 528 hours; SSEF 552=every 552 hours; SSEF 576=every 576 hours; SSEF 600=every 600 hours; SSEF 624=every 624 hours; SSEF 648=every 648 hours; SSEF 672=every 672 hours; SSEF 696=every 696 hours; SSEF 720=every 720 hours; SSEF 744=every 744 hours; SSEF 768=every 768 hours; SSEF 792=every 792 hours; SSEF 816=every 816 hours; SSEF 840=every 840 hours; SSEF 864=every 864 hours; SSEF 888=every 888 hours; SSEF 912=every 912 hours; SSEF 936=every 936 hours; SSEF 960=every 960 hours; SSEF 984=every 984 hours; SSEF 1000=every 10000 hours.

- In the EAP and ALSYMPCA study the median number of Ra-223 injections was 6, 58% and 63% of patients received all 6 injections respectively.

Safety

- Safety profiles in the EAP and ALSYMPCA study were generally comparable (Tables 2 & 3).

Table 2. Summary of safety data

TEAE, n (%)	EAP N=696	ALSYMPCA N=614*
At least one	523 (75)	558 (91)
Grade 3 or 4	263 (38)	329 (53)
Grade 5	47 (7)	97 (16)
Any serious TEAE	243 (35)	281 (46)
TEAEs leading to dose modifications	53 (8)	65 (11)
TEAEs leading to permanent discontinuation	144 (21)	99 (17)

*ALSYMPCA safety population. Deaths reported as TEAEs during the treatment period. TEAE=treatment-emergent adverse events.

Table 3. Summary of most common TEAEs*

TEAE, n (%)	EAP N=696	ALSYMPCA N=614*
Anemia	140 (20)	187 (31)
Bone pain	108 (16)	20 (4)
Nausea	91 (13)	213 (36)
Diarrhea	79 (11)	151 (25)
Fatigue	67 (10)	154 (25)
Decreased appetite	50 (7)	35 (6)
Back pain	50 (7)	20 (3)
Weight decreased	49 (7)	5 (1)
Vomiting	42 (6)	110 (18)
GHSD	33 (5)	14 (2)

*Grading in $\geq 2\%$ of patients in the EAP/ALSYMPCA safety populations. GHSD=general physical health deterioration; TEAE=treatment-emergent adverse events.

Efficacy

- Efficacy data from the EAP and the ALSYMPCA study are summarized in Table 4.
- Due to a shorter follow-up more patients were censored in the EAP than the ALSYMPCA study.
- In the EAP median OS was 16 months and was comparable with that reported in the ALSYMPCA study (Figure 3).
- In post hoc analyses of EAP patients grouped by baseline characteristics:
 - OS was statistically significantly longer in patients with an ALP level of <220 U/L (vs ≥220 U/L), no pain (vs any pain) or who had an ECOG PS 0-1 (vs ≥2), (Figures 4-6)
 - OS was statistically significantly longer for patients treated with concomitant abiraterone (vs no abiraterone, Figure 7) or denosumab (vs no denosumab, Figure 8).

Radium-223 in an international early access program (EAP): Effects of concomitant treatments in mCRPC patients

Fred Saad¹, Joan Carles², Silke Gillespie³
¹University of Montreal Hospital Centers, Montreal, Canada
²Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland

CONCLUSIONS

In an EAP setting in mCRPC patients with bone metastases, Ra-223 was generally well tolerated with no new safety concerns compared with those treated in a randomized placebo controlled clinical trial.

In post hoc analyses OS was longer in patients who were asymptomatic or had ECOG PS of 0-1 or ALP levels <220 U/L.

Data from post hoc analyses revealing improved OS in patients treated with Ra-223 and concomitant denosumab or abiraterone are preliminary. These findings warrant further investigation of these treatment combinations in clinical trials.

BACKGROUND

- Radium-223 dichloride (Ra-223) is the first α -emitter approved for use in mCRPC patients with visceral metastases.
- In the pivotal ALSYMPCA study¹ treating mCRPC bone metastases with Ra-223 and best standard of care (SOC) showed:
 - Improved overall survival (OS, median 14.9 months; hazard ratio=0.70; p<0.001)
 - Delayed time to first symptomatic skeletal event
 - Was generally well tolerated with minimal toxicity
- Safety and efficacy data of Ra-223 are presented in patients enrolled from 15 countries


STUDY OBJECTIVES

- Primary outcome measures were safety and OS
- Planned exploratory analyses included:
 - Time to first skeletal related event (SRE)
 - Changes in total alkaline phosphatase (ALP) and prostate specific antigen (PSA) levels from baseline
 - Time to ALP/PSA progression
- Post hoc analyses included OS in subgroups by:
 - Concomitant medication at baseline (abiraterone and bisphosphonates)
 - Baseline total ALP values
 - Baseline Eastern Cooperative Oncology Group performance status
 - Baseline pain

PATIENTS AND METHODS

- This was a phase 3b, international, prospective, multicenter EAP (Figure 1).
- Eligibility criteria were generally similar to the pivotal trial with the exception that asymptomatic patients were included.
- Analysis of variables was by descriptive statistics.
- The study was terminated on regulatory approval 30 days from the last patient treated.

Figure 1. Study design




¹ SOC: according to local clinical practice. If chemotherapy/adjuvant therapy is considered SOC, Ra-223 must be discontinued. Adverse events were coded according to MedDRA version 17.1 and graded by NCI CTCAE version 4.03.

ALP=alkaline phosphatase; CRPC=castration-resistant prostate cancer; SOC=standard of care; SRE=skeletal related event; ECOG PS=Eastern Cooperative Oncology Group performance status; MedDRA=medical dictionary for regulatory activities; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; PSA=prostate specific antigen; OS=overall survival; SRE=skeletal related event; QoL=QoL; EAP=early access program; SOC=standard of care; SRE=skeletal related event; SRE=skeletal related event; SRE=skeletal related event.

Characteristic	OS (months)	95% CI
Biphosphonates	122 (18)	20 (41)
Denosumab	138 (20)	NA
Abiraterone	156 (22)	NA
Ezoicetamide	122 (18)	NA
Prior radiotherapy	480 (70)	208 (50)
Prior systemic anticancer therapy	677 (87)	NA

- In post hoc analyses of EAP patients grouped by baseline characteristics:
 - OS was statistically significantly longer in patients with an ALP level of <220 U/L (vs >220 U/L, no pain [vs any pain] or who had an ECOG PS 0-1 (vs ≥2), (Figures 4-6)).
 - OS was statistically significantly longer for patients treated with Ra-223 and concomitant abiraterone (vs no abiraterone, Figure 7) or denosumab (vs no denosumab, Figure 8).





Effects of concomitant treatments in mCRPC patients



¹Charité University Medicine Berlin, Berlin, Germany; ²Karolinska University Hospital, Stockholm, Sweden; ³Charité University Medicine Berlin, Berlin, Germany

Abstract 5034

ALSYMPCA	OS (months)	95% CI
Patients, n	143	(NA)
No. of events (%)	15.6	(13.5-18.0)
Median OS, months (95% CI)	NA	(16-NA)
NA	7.4	(NA)
3.6	(NA)	
125	(17)	
38	(8)	



ALSYMPCA	OS (months)	95% CI
Patients, n	143	(NA)
No. of events (%)	15.6	(13.5-18.0)
Median OS, months (95% CI)	NA	(16-NA)
NA	7.4	(NA)
3.6	(NA)	
125	(17)	
38	(8)	



CONCLUSIONS

- In an EAP setting in mCRPC patients with bone metastases, Ra-223 was generally well tolerated with no new safety concerns compared with those treated in a randomized placebo controlled clinical trial.
- In post hoc analyses OS was longer in patients who were asymptomatic or had ECOG PS of 0-1 or ALP levels <220 U/L.
- Data from post hoc analyses revealing improved OS in patients treated with Ra-223 and concomitant denosumab or abiraterone are preliminary. These findings warrant further investigation of these treatment combinations in clinical trials.

REFERENCES

- Parker C, et al N Engl J Med 2013;369:213-23.
- Sartor O, et al Lancet Oncol 2014;15:738-46.

ACKNOWLEDGMENTS

The study was sponsored by Bayer HealthCare AG. Medical writing assistance was provided by Dr Paul Hoban, of Cancer Communications and Consultancy Ltd, Knutsford, UK, and funded by Bayer HealthCare AG.

Copy of this poster obtained through Quick Response code (QR) can be reproduced only and may not be reproduced without the permission from ASCO and the authors of this poster.

RADIUM 223
International EAP
International Equivalency Access Program

Summary of patient enrollment*

Countries	Number of sites	Number of patients enrolled	Number of patients treated
Germany	20	155	124
United Kingdom	8	44	31
Poland	2	11	10
Italy	13	56	48
Spain	19	117	90
Canada	5	29	21
Belgium	5	12	11
Netherlands	2	18	16
Sweden	10	110	95
Norway	5	55	54
Israel	8	101	84
Switzerland	8	52	48
Finland	5	44	38
Ireland	3	35	26
Totals n=14	113	839	696

*Listed in order of ascending site number

Overview of EAP program

	US EAP	International EAP
Clinical study phase	2	3b
No. of patients (screened)	252	839
No. of patients (treated)	184	696
Patient diagnosis	Symptomatic , progressive, bone-predominant, metastatic CRPC/HRPC with ≥ 2 skeletal metastases on imaging with no lung, liver, and/or brain metastases (lymph node only metastasis allowed)	Progressive, bone-predominant, metastatic CRPC/HRPC with ≥ 2 skeletal metastases on imaging with no lung, liver, and/or brain metastases (lymph node only metastasis allowed)
Definition of symptomatic	Regular use of analgesics for cancer-related bone pain Treatment with EBRT for bone pain within last 12 weeks before treatment	Not applicable Symptomatic disease is not a requirement of the study
Primary variables	Acute (during treatment period up to 30 days post-treatment) and long-term (30 days post-treatment and onward) safety	Acute (during treatment period up to 30 days post-treatment) and long-term (30 days post-treatment and onward) safety Overall survival

SAFETY DATA

Summary of TEAEs

Adverse events*	Int EAP [†] N=696		ALSYMPCA N=901			
			Radium 223 [‡] (n=600)		Placebo (n=301)	
Patients with at least one TEAE	523	75%	558	93%	290	96%
Grade 3	232	33%	207	35%	121	40%
Grade 4	31	4%	53	9%	16	5%
Grade 5 (death)	34	5%	97	16%	66	22%
Any serious TEAE	243	35%	281	47%	181	60%
TEAEs leading to dose modifications [§]	53	8%	65	11%	35	11%
TEAEs leading to permanent discontinuation	144	21%	99	17%	62	21%
Patients with any treatment-related TEAE	281	40%	380	63%	171	57%
Grade 3	78	11%	82	14%	32	11%
Grade 4	8	1%	15	3%	2	1%
Grade 5 (AE that resulted in death)	1	<1%	7	1%	0	
Any serious related TEAEs	34	5%	72	12%	30	10%
Related leading to dose modifications [§]	18	3%	NA		NA	
Related leading to permanent discontinuation	38	5%	NA		NA	

Data are n, %; NA, not available

*Treatment emergent adverse events (TEAEs) were coded by System Organ Class and preferred term by MedDRA version 17.1, and graded by CTCAE version 4.03 in the EAP study and graded by CTCAE version 3 in the ALSYMPCA study; [†]Safety analysis set; [‡]Safety population; [§]Including interruptions

Treatment-related AEs of interest

SOC/preferred term	Int-EAP* N=696								ALSYMPCA [†] (Radium 223 arm) N=600							
	Any grade		Grade 3		Grade 4		Grade 5		Any grade		Grade 3		Grade 4		Grade 5	
Blood and lymphatic system	82	12%	38	5%	6	<1%	0		139	23%	52	9%	17	3%	1	<1%
Anemia	65	9%	30	4%	0		0		109	18%	45	8%	3	1%	0	
Thrombocytopenia	20	3%	7	1%	4	<1%	0		43	7%	12	2%	13	2%	1	<1%
Leukopenia	11	2%	3	<1%	0		0		18	3%	6	1%	1	<1%	NA	NA
Neutropenia	8	1%	4	<1%	1	<1%	0		23	4%	6	1%	2	<1%	NA	NA
Gastrointestinal disorders [‡]	136	20%	10	1%	0		1	<1%	233	38%	16	3%	0		1	<1%
Diarrhea	62	9%	3	<1%	0		0		97	16%	6	1%	0		NA	NA
Constipation	9	1%	1	<1%	0		0									

Data presented are n, %

*Safety analysis set; [†]Safety population; [‡]All other preferred terms under this category were <1% AE, adverse event; NA, not available; SOC, System Organ Class

TEAEs leading to discontinuation in $\geq 1\%$ patients

Preferred term	Int EAP*		ALSYMPCA (Radium 223 arm) [†]	
	N=696		N=600	
Any event	144	21%	99	17%
Anemia	15	2%	14	2%
Thrombocytopenia	11	2%	10	2%
Neutropenia	3	<1%	3	1%
Fatigue	1	<1%	5	1%
Bone pain	5	<1%	5	1%
Spinal cord compression	6	<1%	8	1%
Metastasis to the liver	NA		3	1%

Data presented are n, %


*Safety analysis set; [†]ITT population, data reported in Parker et al NEJM 2013; 369:213-22

NA, not available

EFFICACY ANALYSIS

In the INT EAP, overall survival was significantly longer for patients asymptomatic for pain

	Baseline pain (N=669)		
	No pain	Mild-moderate	Severe
Patients, n	146	360	163
No of events (%)	25 (17%)	104 (29%)	72 (44%)
No of censored patients (%)	121 (83%)	256 (71%)	91 (56%)
Median OS, months (95% CI)	NA (16–NE)	15 (13–NE)	11 (8–12)



	No pain	Mild-moderate	Severe	
146	104	29	1	0
360	236	72	7	0
163	90	19	0	0


*Measured by the Brief Pain Inventory Short Form (BPI-SF question 3 “Worst pain in the last 24 hours.” Scores: no pain=0, mild-moderate pain=1 to 6, and severe pain=7 to 10). †No vs all pain.

NA: not achieved; NE: not estimated; OS: overall survival.

1. Saad F, et al. ASCO 2015, Abs 5034.

Overall survival by total ALP*

	Total ALP (N=694)	
	<220 U/L	≥220 U/L
Patients, n	431	263
No of events (%)	95 (22%)	115 (44%)
No of censored patients (%)	336 (78%)	148 (56%)
Median OS, months (95% CI)	NA (NE)	10 (9–11)



Patients at risk


Time (Months)	<220 U/L	≥220 U/L
0	431	263
6	297	149
12	92	33
18	4	4
24	0	0

*Post hoc analysis

ALP, alkaline phosphatase; NA, not available; NE, not estimated (due to censored data); OS, overall survival

Overall survival by current use of bisphosphonates*

	Current use of bisphosphonates (N=696)	
	Yes	No
Patients, n	122	574
No of events (%)	34 (28%)	176 (31%)
No of censored patients (%)	88 (72%)	398 (69%)
Median OS, months (95% CI)	NA (11–NE)	15 (13–NE)



Patients at risk


	0	6	12	18	24
Yes	122	78	19	1	0
No	574	369	106	7	0

*Post hoc analysis

NA, not available; NE, not estimated (due to censored data); OS, overall survival

Overall survival by current use of denosumab*

	Current use of denosumab (N=696)	
	Yes	No
Patients, n	138	558
No of events (%)	35 (25%)	175 (31%)
No of censored patients (%)	103 (75%)	383 (69%)
Median OS, months (95% CI)	NA (15–NE)	13 (12–NE)



Patients at risk


	0	6	12	18	24
Yes	138	104	41	3	0
No	558	343	84	5	0

*Post hoc analysis

NA, not available; NE, not estimated (due to censored data); OS, overall survival

Overall survival by current use of abiraterone*

	Current use of abiraterone (N=696)	
	Yes	No
Patients, n	156	540
No of events (%)	35 (22%)	175 (32%)
No of censored patients (%)	121 (78%)	365 (68%)
Median OS, months (95% CI)	NA (16–NE)	14 (12–16)



Patients at risk


	0	6	12	18	24
Yes	156	119	45	4	0
No	540	328	80	4	0

*Post hoc analysis

NA, not available; NE, not estimated (due to censored data); OS, overall survival

Overall survival by current use of enzalutamide*

	Current use of enzalutamide (N=696)	
	Yes	No
Patients, n	30	666
No of events (%)	9 (30%)	201 (30%)
No of censored patients (%)	21 (70%)	465 (70%)
Median OS, months (95% CI)	16 (10–NE)	15 (13–NE)



Patients at risk

	0	6	12	18	24
Yes	30	24	7	1	0
No	666	423	118	7	0


*Post hoc analysis

NA, not available; NE, not estimated (due to censored data); OS, overall survival


US EAP and ALSYMPSA Update: Median OS appeared to correlate with number of radium-223 injections received

- In both US EAP and ALSYMPSA, median OS appeared to be prolonged in patients receiving 5-6 vs 1-4 injections of radium-223

US EAP: Radium-223 Patients Who Received 1-4 vs 5-6 Injections



ALSYMPSA: Radium-223 Patients Who Received 1-4 vs 5-6 Injections



US, United States; EAP, expanded access program; ALSYMPSA: ALPharadin in SYMptomatic Prostate Cancer; OS, overall survival; NE, not estimable.

Sartor O, et al. Baseline characteristics, number of radium-223 injections, and overall survival in US Expanded Access Program and ALSYMPSA. In: Proceedings of the 18th European Cancer Congress; Sept 25-29, 2015; Vienna, Austria. Abstract 2530.

Summary

- This post hoc subgroup analysis in US EAP and ALSYMPCA patients receiving 1-4 vs 5-6 injections of radium-223 suggests
 - Patients with more advanced CRPC and symptomatic bone metastases are less likely to receive the recommended 6 injections of radium-223, the regimen associated with longer OS
 - US EAP: ≥ 3 prior anticancer therapies, baseline ECOG PS ≥ 2 , lower baseline hemoglobin
 - ALSYMPCA: higher log LDH, lower albumin, baseline ECOG PS ≥ 2 , and higher log PSA

Interim Results from eRADiCate: an Open-Label Phase 2 Study of Radium Ra 223 dichloride with Concurrent Administration of Abiraterone Acetate Plus Prednisone in Castration-Resistant Prostate Cancer Subjects with Symptomatic Bone Metastases

Neal D. Shore,¹ Ronald F. Tutrone,² Neil F. Mariados,³ Luke T. Nordquist,⁴ Bryan A. Mehlhaff,⁵ Stacey S. Harrelson,¹

¹Carolina Urologic Research Center, Myrtle Beach, SC, ²Chesapeake Urology Research Associates, Towson, MD, ³GU Research Network, Omaha, NE, ⁴Associated Medical Professionals of NY, Syracuse, NY, ⁵Oregon Urology Institute, Springfield, OR

INTRODUCTION AND OBJECTIVES

Radium Ra 223 dichloride (Ra-223), an intravenous α -emitting radioisotope, is a calcium mimetic, forming complexes with hydroxyapatite at sites of bone metastases (mets) for castration-resistant prostate cancer (CRPC) patients.

Abiraterone Acetate (AA), an oral androgen receptor inhibitor, decreases serum testosterone for CRPC patients.

Potential synergy of their respective mechanisms of action exists in combining Ra-223 and AA plus prednisone. In addition to this study, an evidence-based approach to assess the consequences of the combined treatment is ongoing in a large phase 3 study. The combination potentially optimizes the benefits of these agents within the therapeutic paradigm for patients with symptomatic metastatic castrate resistant prostate cancer (mCRPC).

This prospective study evaluates the combinatorial use of concurrent Ra-223 and AA plus prednisone in CRPC patients with symptomatic bone metastases in both the pre- and post- chemotherapy settings. Both survival prolonging therapeutics are approved by the US Food and Drug Administration for this indication.

BACKGROUND

Abiraterone Acetate

Abiraterone Acetate (an androgen receptor inhibitor) plus prednisone delays patient-reported pain progression and [health-related quality-of-life] deterioration in patients with metastatic castration-resistant prostate cancer, as well as demonstrates a survival benefit.^{1,2}

Radium Ra 223 Dichloride

Radium-223 dichloride (radium-223), a targeted α -emitter, improves overall survival and is well tolerated in patients with symptomatic castration-resistant prostate cancer with bone metastases.³

Statistical analysis provided by :

Department of Data Management & Statistical Analysis, American Urological Association, Linthicum, MD, USA.

METHODS

eRADiCate is an open-label, phase 2 prospective study (NCT02097303) of subjects with symptomatic bone mCRPC without visceral metastases conducted over approximately 8 months. All subjects are treated with Rad-223 every 4 weeks x 6 doses and concurrent AA plus prednisone BID.

The protocol defined primary efficacy outcome is QOL and bone pain assessments tracked using BPI-SF and FACT-P questionnaires.

Secondary endpoints include:

- Safety
- Time to measurable disease progression and SREs
- PSA and ALP progression
- Progression to further antineoplastic therapy
- Performance status (ECOG) changes

All adverse events and safety analysis are reported and performed from the first Rad-223 infusion through the End of Treatment visit for subjects who have received at least one infusion of Ra-223. Subjects are assessed at screening, weeks 1, 5, 9, 13, 17, 21 and 25. Time to event variables are summarized using the Kaplan-Meier methodology to estimate the median, 25th and 75th percentiles and the minimum and maximum times to events.

RESULTS


Of the 36 subjects enrolled, 30 have received all 6 cycles of Rad-223 with concurrent AA and completed the end of treatment visit, and are thus evaluable at this time.

Bone pain assessments:

- Subjects have reported an overall decrease in reported bone pain from the screening visit through the end of the study visit.
- Significant decreases are also seen in the amount of bone pain that interferes with: Work, General activity, and Mood.
- Per the BPI-SF scores, subjects have experienced No significant increases in how pain interferes with daily their lives.
- The Brief Pain Inventory table shows a significant decrease ($p = 0.014$) in self assessed average bone pain during this period.

Quality of life assessments:

- There have been significant increases in quality of life measures from the screening visit through the end of study visit
- Subjects have reported less pain, less life interferences and increased sleep quality



Brief Pain Inventory (Short form) Results

Variable	Screening Rating	End of Treatment Rating	Change	p-value
BPI Worst	3.4	2.5	-0.9	0.134
BPI Least	2.1	1.6	-0.5	0.234
BPI Average	3.0	1.9	-1.0	0.014
BPI Now	1.8	1.3	-0.5	0.267
BPI Active	2.7	1.5	-1.3	0.013
BPI Mood	2.3	1.4	-0.9	0.045
BPI Walk	2.5	2.2	-0.3	0.343
BPI Work	2.9	2.1	-0.8	0.019
BPI Relate	1.7	1.3	-0.4	0.263
BPI Sleep	2.4	1.5	-0.8	0.128

BPI Values range from 0 to 10

Clinically Significant Abnormalities

Cycle	ALP	Potassium	AST	ALT	Hgb	WBC	PLT
Screening	0	0	0	0	0	0	0
Cycle 1/Week 1	0	0	1	1	0	0	0
Cycle 2/Week 5	1	0	0	0	0	0	0
Cycle 3/Week 9	0	0	0	0	1	1	0
Cycle 4/Week 13	0	0	0	0	0	0	0
Cycle 5/Week 17	0	0	1	0	1	0	0
Cycle 6/Week 21	0	0	0	0	0	1	0
End of Treatment	0	0	0	0	1	1	0

CONCLUSIONS

The primary purpose of the eRADiCate study is to evaluate the combined treatment regimen: Rad-223 with concurrent AA plus prednisone. 30 of the 36 subjects enrolled have received all 6 cycles of Rad-223 and completed the EOT visit, and are thus evaluable. This is an interim report.

eRADiCate subjects experienced improvements in both of the chosen efficacy end points:

- Decreased bone pain
- Improved quality of life

eRADiCate subjects also demonstrated:

- Stability in ECOG scores
- A paucity of clinically significant serological parameters associated with these 2 therapeutics

References

1. Ryan AJ et al. N Engl J Med 2013; 368: 138-148.
2. Basch E et al. Lancet Oncol 2013; 14: 1193-1199.
3. Nilsson S et al. Clin Adv Hematol Oncol 2014; 14: 12(4 Suppl 11):9-10.

Poster presented at the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) in San Francisco, CA, USA, January 7-9, 2016

This Investigator Initiated Study was funded by Bayer HealthCare Pharmaceuticals

Randomized open label phase II trial of radium-223 with concurrent administration of abiraterone acetate plus prednisone in symptomatic CRPC patients with bone metastasis (eRADicAte)

Principal Investigator: Neal Shore

Sponsor: Carolina Research Professionals, Myrtle Beach, SC

NCT02097303

17355 – Shore

**Randomized open label phase II trial of radium-223 with concurrent administration of abiraterone acetate plus prednisone in symptomatic CRPC patients with bone metastasis
(N=30 - Actual=36)**

Study objectives

Primary endpoints:

To investigate the efficacy of concurrent treatment with Radium Ra 223 dichloride and Abiraterone Acetate (AA) plus Prednisone. Efficacy will be assessed by tracking bone pain assessments and quality of life questionnaires.

Secondary endpoints:

To measure safety, time to measurable disease progression, SREs, PSA progression, Changes and time to total ALP progression, progression to additional neoplastic therapy

17355 – Shore Methods

In this open-label, phase 2 study, 36 patients with symptomatic bone mCRPC with no visceral mets were enrolled. All evaluable patients are treated with Rad-223 every 4 weeks x6 doses, and concomitant AA 1000mg + prednisone 5 mg BID.

The primary endpoint is efficacy, assessed by tracking bone pain assessments and quality of life (QoL) using BPI-SF and FACT-P questionnaires.

Secondary endpoints include:

- Safety
- Time to measurable disease progression and SREs
- PSA and ALP progression
- Progression to further antineoplastic therapy
- Performance status (ECOG) changes

At interim analysis, subjects in this study experienced improvements in both of the chosen efficacy assessments:

- a decrease in bone pain
- an improvement in their quality of life

Treatment of symptomatic bone mCRPC subjects with concurrent Rad-223 and AA plus prednisone has also demonstrated:

- a stability in ECOG scores
- A paucity of clinically significant serological parameters associated with these 2 therapeutics

- The combined treatment has not produced significant adverse events that can be directly linked to the combined treatment regimen. Thus far, any observed adverse events occurred after 2 months of treatment, on average.
- None of the evaluable subjects have progressed nor require further treatment during the trial
- Subjects did not experience any SREs

3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride in Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases From ALSYMPCA

Presented by: Neal Shore, MD
*Carolina Urologic Research Center, Myrtle
Beach, SC, USA*

Overall Survival

- Similar proportions of radium-223 (41/142 [29%]) and placebo (21/64 [33%]) patients died during and within 30 days of completing chemotherapy
- Median OS from start of chemotherapy was 16.0 months post–radium-223 and 15.8 months post-placebo (HR = 1.23; 95% CI, 0.86-1.75)

Conclusions

- Safety of chemotherapy post–radium-223 assessed in post hoc analysis showed no detrimental effects on hematology or OS
- Findings indicate that chemotherapy can be administered safely after radium-223

Thank You